MesenCure™

MesenCure™: Cell Therapy Reinvented

Path 41 Our intimate understanding of the biology, prospects, and challenges facing cell therapies allowed us to take this field a giant leap forward, inventing MesenCure™ - an enhanced mesenchymal stromal cell therapy for acute inflammations.
Path 42

MesenCure™: Cell Therapy Reinvented

What makes MesenCure™ so unique?

Professionalization that makes the cells more responsive to inflammation
Effective regulation of the immune system at multiple levels
Encourages the regeneration of blood vessels, epithelial and other tissues
Can treat up to 100 thousand patients from a single donor cell-bank

Electron microscopy image of a highly active MesenCure cell

MesenCure reduces the infiltration of immune cells into the lungs healing pneumonia within less than 24 hours

MesenCure™ is the first to show significant and clinically-meaningful outcomes in severe COVID

We developed processes to enhance the natural ability of adipose mesenchymal stromal cells to control inflammation and encourage tissue regeneration by 'educating' them before they are injected into the patient body.

Once infused, MesenCure cells rapidly reach the lungs of the severe COVID patient, where they sense the level of inflammation and respond by secreting proteins with anti-inflammatory activity.

MesenCure™ soothes life-threatening pneumonia in severe COVID patients leading to a dramatic reduction in the mortality in these patients by nearly 70% and cutting the hospitalization time of the most complicated patients by almost 40% {Read more >> clinical studies/mesencure}

By saving and improving patients' lives, freeing hospital and ICU beds to care for other patients, and reducing hospitalization and long-term healthcare costs, MesenCure brings considerable benefits for patients, healthcare providers, and payers alike.

MesenCure™ can help a life-threatening complication seen in cancer patients

Inflammatory overreaction or cytokine release syndrome (CRS) develops in up to 78% of cancer patients treated with biological immunotherapies (CAR-T or BiTEs) that galvanize the immune system to fight cancer as well as in patients transplanted with blood-forming stem cells (HSCT). Up to 27% of cancer patients, who suffer from this condition, may develop a multi-system failure that could endanger their lives.

In a preclinical trial conducted at The Jackson Laboratory in California, one of the world's most respected research institutes, it was found that MesenCure™ significantly reduced the inflammatory overreaction that developed following biological cancer treatment with complete response, demonstrating its potential to prevent life-threatening conditions in patients.

We’re continuing our research and development of MesenCure™ for other applications that afflict millions and patients yearly involving acute inflammations and tissue degeneration.

Pipeline